VahatiCor — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VahatiCor is a clinical-stage medical device company targeting the significant unmet need in Coronary Microvascular Dysfunction (CMD), a condition affecting millions worldwide with debilitating chest pain. Its core innovation is the A-FLUX Reducer System, which utilizes proprietary SwiftCell® technology—a shape-memory, hourglass-shaped implant placed in the coronary sinus to immediately modulate blood flow and alleviate symptoms. The company recently secured an oversubscribed Series B financing to accelerate its early feasibility study (SERRA-I) and engineering development, positioning it to advance a novel interventional therapy in the cardiovascular space.

Cardiovascular

Technology Platform

The A-FLUX Reducer System with SwiftCell® Technology: a minimally invasive, shape-memory, hourglass-shaped implant designed for placement in the coronary sinus to immediately redistribute cardiac blood flow and relieve symptoms of Coronary Microvascular Dysfunction.

Opportunities

The primary opportunity is addressing the vast, underserved multi-billion dollar global market for Coronary Microvascular Dysfunction (CMD), where millions of patients lack effective interventional treatment options.

Success in clinical trials could position VahatiCor as a pioneer in device-based CMD therapy, enabling rapid market penetration and potential strategic interest from larger cardiovascular device companies.

Risk Factors

Key risks include clinical/regulatory risk, as the investigational device must prove safe and effective in trials to gain FDA approval; technology/adoption risk, requiring proof of mechanism and clinician uptake; and financing risk, as the pre-revenue company remains dependent on external capital to fund expensive development and trials.

Competitive Landscape

The competitive landscape for device-based CMD treatment is currently nascent. The most analogous competitor is Neovasc's Reducer device, approved for refractory angina, which validates the coronary sinus modulation concept but targets a different patient subset. VahatiCor's primary competition is the current standard of care: pharmacological management. If successful, it may face future competition from other novel devices or drug therapies entering the CMD space.

More companies in Digital Health & Biotech SaaS →More companies in United States →